| |
Article Title |
Author(s) |
Pages |
|
|
|
Metaiodobenzylguanidine in the diagnosis and therapy of neuroendocrine tumors
The impact of the interest in molecular imaging is in its infancy. New molecules that can be labeled with either imaging or therapeutic radionuclides are being developed to interact with specific meta...
|
R. Edward Coleman
|
S1
|
|
|
|
Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors
Abstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are slow-growing neoplasms that arise from the neuroendocrine system of the gastrointestinal tract and pancreas. These may be classifie...
|
Daniel Pryma,
Chaitanya Divgi
|
S3-S8
|
|
|
|
Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy
Abstract: [131I]meta-Iodobenzylguanidine ([131I]MIBG) has been used for the therapy of tumors of neuroectodermal origin since the 1980s. Its role in the management of these malignancies remains contro...
|
Rob J. Mairs,
Marie Boyd
|
S9-S20
|
|
|
|
Current experience with mIBG therapy in combination with chemotherapy and radiosensitizers
Abstract: Introduction: [131I]meta-iodobenzylguanidine ([131I]mIBG) has been used for decades to treat childhood neuroblastoma and adult neuroendocrine tumors, which express the norepinephrine transpo...
|
Mark N. Gaze,
Naomi L. Fersht
|
S21-S26
|
|
|
|
A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors
Abstract: Pheochromocytomas/paragangliomas are rare tumors; most are sporadic. Biochemical proof of disease is better with measurement of plasma metanephrines and less cumbersome than determinations i...
|
Ioannis Ilias,
Karel Pacak
|
S27-S34
|
|
|
|
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
Abstract: Introduction: Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use o...
|
Steven G. DuBois,
Katherine K. Matthay
|
S35-S48
|
|
|
|
Meta[131I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma
Abstract: Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are tumors that can exhibit a malignant behavior. Targeted radiotherapy with 131I-metaiodobenzylguanidine (131I-MIBG) has pr...
|
Robert E. Goldsby,
Paul A. Fitzgerald
|
S49-S62
|
|
|
|
Radioiodinated MIBG in paraganglioma and pheochromocytoma: previous results and early experiences using no-carrier-added MIBG
Abstract: The majority of pheochromocytomas and paragangliomas are benign, with malignancy occurring in approximately 10% of pheochromocytoma patients. The malignancy rate among paragangliomas is 15–3...
|
Olga James,
R. Edward Coleman
|
S63-S76
|
|
|
|
Diagnosis and therapy of carcinoid tumors—current state of the art and future directions
Abstract: Carcinoid tumors account for less than 1% of all malignancies and the majority arise in the gastrointestinal system. These tumors are slow growing compared with adenocarcinomas and they diff...
|
Mazhar U. Khan,
R. Edward Coleman
|
S77-S91
|
|
